Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Website: instilbio.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -53.8% (LTM)

Entry Point: Share price is 2 411.9% higher than minimum and 90.6% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: TIL
Share price, USD:  (-0.9%)7.93
year average price 14.91  


year start price 34.23 2025-06-13

max close price 34.23 2025-06-13

min close price 7.06 2026-01-22

current price 7.93 2026-06-12
Common stocks: 130 079 097

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 1 032
Net Debt ($m): -53
EV (Enterprise Value): 979
Price to Book: 8.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-03globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

2025-08-13globenewswire.com

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2025-07-02globenewswire.com

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

2025-05-25seekingalpha.com

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

2025-03-04globenewswire.com

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

2024-11-05globenewswire.com

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

2024-09-16zacks.com

Instil Bio Stock Skyrockets 641% in One Week: Here's Why

2024-09-14fool.com

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?

2024-09-13seekingalpha.com

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements

2024-08-13globenewswire.com

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-13 2024-11-13 2024-08-13 2024-05-10 2023-11-13 2023-08-14 2023-05-11 2022-11-14 2022-08-12
acceptedDate 2025-11-13 07:08:27 2025-08-13 07:06:16 2025-03-04 07:42:05 2024-11-13 07:39:58 2024-08-13 17:16:42 2024-05-10 07:10:33 2024-03-21 17:05:50 2023-11-13 17:03:23 2023-08-14 07:05:14 2023-05-11 07:09:31 2023-03-31 07:38:45 2022-11-14 16:17:06 2022-08-12 07:23:11 2022-03-07 07:14:20 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 138 000
costOfRevenue 12 000 0 0 0 1 000 000 993 000 0 953 000 835 000 0 6M 0 0 0 0
grossProfit -12 000 0 0 0 -1 000 000 -993 000 0 -953 000 -835 000 0 -6M 0 0 0 138 000
grossProfitRatio 0 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 9M 7M 12M 10M 3M 7M 40M 8M 8M 21M 141M 40M 42M 107M 19M
generalAndAdministrativeExpenses 6M 6M 44M 11M 11M 12M 48M 12M 12M 13M 62M 17M 17M 48M 14M
sellingAndMarketingExpenses 0 0 0 0 0 -993 000 0 0 0 0 0 0 0 3M 0
sellingGeneralAndAdministrativeExpenses 6M 6M 44M 11M 11M 11M 48M 12M 12M 13M 62M 17M 17M 51M 14M
otherExpenses 0 11M 17M 3M -1 000 000 -428 000 72M 46M 628 000 -57 000 -3M 0 0 -3M 0
operatingExpenses 15M 23M 74M 24M 13M 19M 159M 67M 20M 34M 200M 57M 59M 156M 34M
costAndExpenses 15M 23M 74M 24M 14M 20M 159M 67M 20M 34M 206M 57M 59M 156M 34M
interestIncome 893 000 1M 7M 2M 2M 2M 9M 2M 2M 2M 4M 1M 486 000 80 000 70 000
interestExpense 2M 2M 9M 2M 2M 2M 5M -2M 590 000 636 000 2M 807 000 331 000 0 0
depreciationAndAmortization 255 000 12 000 4M 901 000 1 000 000 993 000 5M 953 000 991 000 28M 6M 3M 1M 3M 256 000
ebitda -12M -20M -63M -20M -12M -19M -147M -67M -17M -30M -217M -54M -58M -153M -33M
ebitdaratio 0 0 0 0 0 0 0 0 0 0
operatingIncome -15M -23M -74M -24M -14M -20M -159M -67M -21M -58M -206M -57M -59M -156M -34M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 1M 2M -594 000 610 000 -1M -5M 3M -716 000 -382 000 1M -19M 54 000 -877 000 -1M -4M
incomeBeforeTax -14M -21M -74M -23M -15M -24M -156M -67M -19M -57M -225M -57M -60M -157M -38M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 0 0 0 949 724 0 -953 000 227 000 -742 000 -2M -371 000 -609 000 39 000 151 000
netIncome -14M -21M -74M -23M -15M -24M -156M -67M -19M -56M -223M -56M -59M -157M -38M
netIncomeRatio 0 0 0 0 0 0 0 0 0 0
eps -2.01 -3.24 -11.39 -3.54 -2.29 -3.74 -24 -10.37 -0.14 -0.43 -34.46 -0.43 -0.46 -29.6 -5.89
epsdiluted -2.01 -3.24 -3.54 -2.29 -3.74 -10.37 -0.14 -0.43 -0.43 -0.46
weightedAverageShsOut 7M 7M 7M 7M 7M 7M 7M 7M 130M 130M 6M 130M 129M 5M 6M
weightedAverageShsOutDil 7M 7M 7M 7M 7M 7M 7M 7M 130M 130M 6M 130M 129M 5M 6M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-21 2023-03-31 2022-03-07 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -2M 4M 2M 80 000 70 000
ebit -66M -152M -223M -155M -34M
nonOperatingIncomeExcludingInterest -7M -7M 17M -294 000 0
netIncomeFromContinuingOperations -74M -156M -223M -157M -38M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -74M -156M -223M -157M -38M
epsDiluted -11.39 -24 -34.46 -29.6 -5.89

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-13 2024-11-13 2024-08-13 2024-05-10 2023-11-13 2023-08-14 2023-05-11 2022-11-14 2022-08-12
acceptedDate 2025-11-13 07:08:27 2025-08-13 07:06:16 2025-03-04 07:42:05 2024-11-13 07:39:58 2024-08-13 17:16:42 2024-05-10 07:10:33 2024-03-21 17:05:50 2023-11-13 17:03:23 2023-08-14 07:05:14 2023-05-11 07:09:31 2023-03-31 07:38:45 2022-11-14 16:17:06 2022-08-12 07:23:11 2022-03-07 07:14:20 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 6M 8M 9M 7M 7M 5M 9M 9M 22M 27M 44M 41M 42M 38M 242M
shortTermInvestments 74M 84M 105M 114M 142M 148M 141M 174M 180M 196M 217M 262M 312M 417M 0
cashAndShortTermInvestments 80M 92M 113M 120M 149M 154M 150M 183M 203M 223M 261M 303M 355M 454M 242M
netReceivables 843 000 805 000 0 3M 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 116M 115M 2M 12M 6M 7M 2M 11M 12M 9M 8M 10M 13M 0 0
totalCurrentAssets 196M 207M 124M 133M 155M 161M 161M 196M 221M 240M 269M 314M 368M 464M 246M
propertyPlantEquipmentNet 553 000 740 000 130M 131M 135M 136M 141M 142M 185M 183M 209M 198M 181M 122M 55M
goodwill 0 0 0 0 0 0 0 0 0 0 0 6M 6M 6M 6M
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 10M 10M 10M 10M
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 16M 16M 16M 16M
longTermInvestments 3M 12M 0 3M 4M 8M 23M 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 12M 11M 9M 6M 581 000 2M 639 000 3M 3M 4M 3M 5M 4M 8M 2M
totalNonCurrentAssets 16M 24M 139M 140M 139M 145M 165M 145M 188M 187M 213M 219M 201M 146M 73M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 212M 231M 264M 273M 294M 306M 326M 340M 408M 427M 482M 533M 569M 610M 319M
accountPayables 928 000 523 000 659 000 1M 1M 1M 1M 2M 2M 1M 2M 5M 6M 6M 3M
shortTermDebt 305 000 456 000 0 2M 2M 2M 0 2M 2M 2M 0 2M 2M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 524 000 0
deferredRevenue 0 0 0 0 0 0 0 10M 14M 0 0 0 0 0 0
otherCurrentLiabilities 4M 13M 2M 7M 7M 8M 1M 324 000 459 000 23M 4M 34M 35M 14M 3M
totalCurrentLiabilities 6M 14M 8M 10M 10M 11M 11M 13M 18M 27M 33M 42M 43M 41M 13M
longTermDebt 85M 84M 84M 84M 84M 82M 81M 84M 85M 81M 72M 69M 55M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 555 000 1M 2M 0
otherNonCurrentLiabilities 1M 1M 1M 2M 5M 7M 5M 8M 8M 8M 8M 72M 11M 11M 13M
totalNonCurrentLiabilities 86M 85M 86M 86M 89M 89M 89M 93M 93M 89M 86M 80M 67M 13M 13M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 305 000 462 000 3M 3M 4M 2M 5M 5M 6M 6M 8M 8M 8M 0 0
totalLiabilities 91M 99M 94M 96M 99M 100M 100M 106M 112M 116M 119M 122M 110M 55M 27M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 332M
commonStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
retainedEarnings -718M -705M -655M -643M -620M -605M -581M -568M -501M -482M -425M -371M -315M -202M -45M
accumulatedOtherComprehensiveIncomeLoss -612 000 -805 000 -228 000 -520 000 -627 000 -563 000 -348 000 -525 000 -795 000 -406 000 -493 000 -335 000 -557 000 -87 000 -283 000
othertotalStockholdersEquity 839M 837M 820M 816M 812M 803M 798M 794M 782M 774M
totalStockholdersEquity 120M 132M 169M 176M 195M 206M 226M 234M 297M 311M 364M 411M 458M 555M 292M
totalEquity 120M 132M 169M 176M 195M 206M 226M 234M 297M 311M 364M 411M 458M 555M 292M
totalLiabilitiesAndStockholdersEquity 212M 231M 273M 294M 306M 340M 408M 427M 533M 569M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 212M 231M 264M 273M 294M 306M 326M 340M 408M 427M 482M 533M 569M 610M 319M
totalInvestments 77M 96M 105M 116M 146M 156M 164M 174M 180M 196M 217M 262M 0 417M 0
totalDebt 85M 85M 87M 85M 86M 86M 86M 86M 87M 83M 80M 71M 57M 0 0
netDebt 79M 77M 78M 79M 79M 80M 77M 77M 65M 56M 36M 30M 15M -38M -242M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-21 2023-03-31 2022-03-07 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 9M 9M 0 10M 4M
totalPayables 659 000 1M 2M 6M 3M
otherPayables 0 0 0 524 000 0
accruedExpenses 3M 6M 24M 22M 7M
capitalLeaseObligationsCurrent 2M 2M 2M 0 0
capitalLeaseObligationsNonCurrent 1M 3M 5M 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 825M 807M 789M 757M 6M
otherTotalStockholdersEquity -0 0 0 0 -0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-13 2024-11-13 2024-08-13 2024-05-10 2023-11-13 2023-08-14 2023-05-11 2022-11-14 2022-08-12
acceptedDate 2025-11-13 07:08:27 2025-08-13 07:06:16 2025-03-04 07:42:05 2024-11-13 07:39:58 2024-08-13 17:16:42 2024-05-10 07:10:33 2024-03-21 17:05:50 2023-11-13 17:03:23 2023-08-14 07:05:14 2023-05-11 07:09:31 2023-03-31 07:38:45 2022-11-14 16:17:06 2022-08-12 07:23:11 2022-03-07 07:14:20 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -14M -21M -74M -23M -15M -24M -156M -67M -19M -57M -223M -56M -59M -157M -38M
depreciationAndAmortization 12 000 12 000 4M 901 000 975 000 993 000 5M 953 000 991 000 2M 6M 2M 1M 3M 256 000
deferredIncomeTax 0 0 0 0 0 0 0 45M -2M 0 0 0 0 710 000 0
stockBasedCompensation 2M 2M 17M 4M 4M 5M 18M 5M 4M 5M 30M 8M 8M 26M 2M
changeInWorkingCapital 741 000 -5M -13M -9M -1M 2M -9M 1M -5M -4M -10M 5M 1M 4M 1M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 403 000 237 000 -556 000 -45 000 -9000 20 000 -1M -425 000 753 000 -980 000 -2M -232 000 4M 4M -1M
otherWorkingCapital 338 000 -5M -12M -9M -1M 2M -8M 2M -6M 980 000 -8M 5M 0 499 000 3M
otherNonCashItems 509 000 10M 10M 7M 179 999 9M 60M 668 000 1M 20M 16M 754 000 1M 636 000 5M
netCashProvidedByOperatingActivities -11M -15M -56M -20M -11M -14M -82M -14M -20M -35M -180M -41M -47M -122M -30M
investmentsInPropertyPlantAndEquipment 0 0 -10M 0 0 0 -21M -5M -7M -8M -85M -25M -26M -58M -51M
acquisitionsNet 5000 0 0 -541 000 541 000 0 0 0 0 0 1M 0 0 0 -306 000
purchasesOfInvestments -7M -39M -136M -16M -40M -51M -301M -72M -96M -82M -666M -84M -221M -1 108M 0
salesMaturitiesOfInvestments 25M 38M 199M 47M 52M 60M 362M 80M 114M 105M 865M 135M 226M 691M 0
otherInvestingActivites -10M 13 000 -11M 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 8M -400 000 20M 12M 9M 2M 10M 15M 25M -22M
debtRepayment 0 0 0 0 0 -587 000 -4M 0 0 0
commonStockIssued 378 000 0 0 0 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 7M 159 000 0 0 -587 000 8M 4M 15M 51M
netCashUsedProvidedByFinancingActivities 378 000 7M 159 000 0 0 -587 000 4M 4M 15M 51M
effectOfForexChangesOnCash -25 000 21 000 -94 000 42 000 -8000 -63 000 -201 000 -85 000 -73 000 -24 000 -637 000 -563 000 -873 000 -304 000 559 000
netChangeInCash -2M -8M -61 000 -118 000 1M -5M -33M -13M -5M -16M 6M -1M -19M -204M 233M
cashAtEndOfPeriod 6M 8M 11M 7M 7M 5M 11M 10M 23M 28M 44M 42M 43M 38M 242M
cashAtBeginningOfPeriod 8M 16M 11M 7M 5M 11M 44M 23M 28M 44M 38M 43M 62M 242M 9M
operatingCashFlow -11M -15M -56M -20M -11M -14M -82M -14M -20M -35M -180M -41M -47M -122M -30M
capitalExpenditure 0 0 -10M 0 0 0 -21M -5M -7M -8M -85M -25M -26M -58M -51M
freeCashFlow -11M -15M -66M -20M -11M -14M -103M -20M -27M -43M -265M -66M -73M -180M -80M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-21 2023-03-31 2022-03-07 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 866 000 2M -1M 0 0
netCashProvidedByInvestingActivities 54M 41M 115M -474M -51M
netDebtIssuance 3M 8M 70M 0 0
longTermNetDebtIssuance 3M 8M 70M 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 0 2M 391M 313M
netCommonStockIssuance 0 0 2M 339M 0
commonStockIssuance 0 0 2M 339M 0
netPreferredStockIssuance 0 0 0 52M 313M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -1M 0 0 2M 430 000
netCashProvidedByFinancingActivities 2M 8M 72M 393M 313M
incomeTaxesPaid 0 0 0 0 0
interestPaid 8M 0 0 0 0

Earning call transcript

Press-releases

Show financial reports only

2026-03-27 ET
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-01-06 12:00 ET
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
2025-11-13 12:00 ET
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-09-10 11:00 ET
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
2025-08-13 ET
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-07-31 ET
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
2025-07-02 ET
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
2025-06-11 ET
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
2025-06-02 ET
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
2025-05-30 ET
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
2025-05-23 ET
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
2025-05-22 ET
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipat...
2025-05-13 ET
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-03-04 ET
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2025-01-14 ET
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
2024-11-13 ET
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2024-09-16 ET
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
2024-08-13 ET
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
2024-08-01 ET
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
2024-05-10 ET
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-03-21 21:00 ET
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-01-16 13:00 ET
Instil Bio Announces Strategic Update
2023-12-05 22:00 ET
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
2023-11-13 22:00 ET
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-06 12:00 ET
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
2023-08-14 11:00 ET
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-06-26 20:38 ET
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
2023-05-11 11:00 ET
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
2023-03-31 11:00 ET
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
2023-01-31 22:00 ET
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
2023-01-09 12:00 ET
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
2022-12-12 16:45 ET
Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)
2022-12-08 12:00 ET
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
2022-11-14 21:07 ET
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-11-08 12:00 ET
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2022-10-31 11:00 ET
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing
2022-10-18 11:00 ET
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer
2022-09-19 11:20 ET
Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit
2022-09-09 11:00 ET
Instil Bio to Present at Morgan Stanley Global Healthcare Conference
2022-09-06 11:00 ET
Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer
2022-08-12 11:00 ET
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-05-27 11:00 ET
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
2022-05-18 11:00 ET
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)
2022-05-16 11:00 ET
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-03-07 12:00 ET
Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
2022-03-02 12:00 ET
Instil Bio to Present at the Cowen 42nd Annual Health Care Conference
2021-11-15 12:00 ET
Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-11-15 12:00 ET
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
2021-11-08 13:05 ET
Instil Bio to Present at Upcoming Investor Conferences in November
2021-09-16 11:00 ET
Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress
2021-09-13 11:00 ET
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
2021-09-02 11:00 ET
Instil Bio to Present at Upcoming Investor Conferences in September
2021-08-12 11:00 ET
Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-06-01 11:00 ET
Instil Bio to Present at the Jefferies Virtual Healthcare Conference
2021-05-13 11:00 ET
Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
2021-04-27 11:00 ET
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
2021-04-12 11:18 ET
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting
2021-03-23 21:00 ET
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-03-19 00:26 ET
Instil Bio Announces Pricing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 8
2026-04-03 12:00 ET
Instil Bio, Inc. published news for 2026 q1
SEC form 8
2026-04-03 12:00 ET
Instil Bio, Inc. published news for 2026 q1
SEC form 10
2026-03-27 07:05 ET
Instil Bio, Inc. published news for 2025 q4
SEC form 8
2026-03-27 07:00 ET
Instil Bio, Inc. published news for 2025 q4
SEC form 8
2026-03-27 07:00 ET
Instil Bio, Inc. published news for 2025 q4
SEC form 10
2025-11-13 07:08 ET
Instil Bio, Inc. reported for 2025 q3
SEC form 8
2025-11-13 07:05 ET
Instil Bio, Inc. published news for 2025 q3
SEC form 8
2025-11-13 07:05 ET
Instil Bio, Inc. published news for 2025 q3
SEC form 10
2025-08-13 11:06 ET
Instil Bio, Inc. reported for 2025 q2
SEC form 8
2025-08-13 11:00 ET
Instil Bio, Inc. published news for 2025 q2
SEC form 8
2025-08-13 11:00 ET
Instil Bio, Inc. published news for 2025 q2
SEC form 8
2025-05-27 21:03 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 8
2025-05-27 21:03 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 8
2025-05-22 10:02 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 8
2025-05-22 10:02 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 10
2025-05-13 11:06 ET
Instil Bio, Inc. reported for 2025 q1
SEC form 10
2025-05-13 00:00 ET
Instil Bio, Inc. reported for 2025 q1
SEC form 8
2025-05-13 00:00 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 8
2025-05-13 00:00 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 8
2025-03-28 21:38 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 8
2025-03-28 21:38 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 8
2025-03-28 21:38 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 10
2025-03-04 12:42 ET
Instil Bio, Inc. reported for 2024 q4
SEC form 10
2025-03-04 00:00 ET
Instil Bio, Inc. reported for 2024 q4
SEC form 8
2025-03-04 00:00 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 8
2025-03-04 00:00 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 8
2025-03-04 00:00 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 10
2024-11-13 07:39 ET
Instil Bio, Inc. reported for 2024 q3
SEC form 8
2024-11-13 07:01 ET
Instil Bio, Inc. published news for 2024 q3
SEC form 8
2024-11-13 07:01 ET
Instil Bio, Inc. published news for 2024 q3
SEC form 10
2024-11-13 00:00 ET
Instil Bio, Inc. reported for 2024 q3
SEC form 10
2024-08-13 00:00 ET
Instil Bio, Inc. reported for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Instil Bio, Inc. published news for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Instil Bio, Inc. published news for 2024 q2
SEC form 10
2024-05-10 00:00 ET
Instil Bio, Inc. reported for 2024 q1
SEC form 8
2024-05-10 00:00 ET
Instil Bio, Inc. published news for 2024 q1
SEC form 8
2024-05-10 00:00 ET
Instil Bio, Inc. published news for 2024 q1
SEC form 10
2024-03-21 00:00 ET
Instil Bio, Inc. reported for 2023 q4
SEC form 8
2024-03-21 00:00 ET
Instil Bio, Inc. published news for 2023 q4
SEC form 8
2024-03-21 00:00 ET
Instil Bio, Inc. published news for 2023 q4
SEC form 10
2023-11-13 17:03 ET
Instil Bio, Inc. reported for 2023 q3
SEC form 8
2023-11-13 17:00 ET
Instil Bio, Inc. published news for 2023 q3
SEC form 10
2023-11-13 00:00 ET
Instil Bio, Inc. reported for 2023 q3
SEC form 10
2023-08-14 07:05 ET
Instil Bio, Inc. reported for 2023 q2
SEC form 6
2023-08-14 07:01 ET
Instil Bio, Inc. reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Instil Bio, Inc. reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Instil Bio, Inc. reported for 2023 q2
SEC form 6
2023-06-26 16:32 ET
Instil Bio, Inc. published news for 2023 q1
SEC form 6
2023-06-14 16:31 ET
Instil Bio, Inc. published news for 2023 q1
SEC form 10
2023-05-11 07:09 ET
Instil Bio, Inc. reported for 2023 q1
SEC form 6
2023-05-11 07:05 ET
Instil Bio, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Instil Bio, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Instil Bio, Inc. reported for 2023 q1
SEC form 6
2023-04-24 16:30 ET
Instil Bio, Inc. published news for 2023 q1
SEC form 6
2023-04-14 16:29 ET
Instil Bio, Inc. published news for 2023 q1
SEC form 10
2023-03-31 07:38 ET
Instil Bio, Inc. reported for 2022 q4
SEC form 6
2023-03-31 07:07 ET
Instil Bio, Inc. reported for 2022 q4
SEC form 10
2023-03-31 00:00 ET
Instil Bio, Inc. reported for 2022 q4
SEC form 8
2023-03-31 00:00 ET
Instil Bio, Inc. reported for 2022 q4
SEC form 6
2023-03-10 15:47 ET
Instil Bio, Inc. published news for 2022 q4
SEC form 6
2023-02-27 17:06 ET
Instil Bio, Inc. published news for 2022 q4
SEC form 6
2023-02-01 17:01 ET
Instil Bio, Inc. published news for 2022 q4
SEC form 6
2023-01-27 17:00 ET
Instil Bio, Inc. published news for 2022 q4
SEC form 6
2023-01-09 16:00 ET
Instil Bio, Inc. published news for 2022 q4
SEC form 6
2022-12-08 17:00 ET
Instil Bio, Inc. published news for 2022 q3
SEC form 10
2022-11-14 16:17 ET
Instil Bio, Inc. reported for 2022 q3
SEC form 6
2022-11-14 16:05 ET
Instil Bio, Inc. reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Instil Bio, Inc. reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Instil Bio, Inc. reported for 2022 q3
SEC form 6
2022-11-08 16:35 ET
Instil Bio, Inc. published news for 2022 q3
SEC form 6
2022-10-31 07:24 ET
Instil Bio, Inc. published news for 2022 q3
SEC form 6
2022-10-18 17:01 ET
Instil Bio, Inc. published news for 2022 q3
SEC form 6
2022-09-06 17:41 ET
Instil Bio, Inc. published news for 2022 q2
SEC form 6
2022-09-06 17:23 ET
Instil Bio, Inc. published news for 2022 q2
SEC form 6
2022-09-06 17:00 ET
Instil Bio, Inc. published news for 2022 q2
SEC form 10
2022-08-12 07:23 ET
Instil Bio, Inc. reported for 2022 q2
SEC form 6
2022-08-12 07:03 ET
Instil Bio, Inc. reported for 2022 q2
SEC form 10
2022-08-12 00:00 ET
Instil Bio, Inc. reported for 2022 q2
SEC form 8
2022-08-12 00:00 ET
Instil Bio, Inc. reported for 2022 q2
SEC form 6
2022-06-13 17:08 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 6
2022-05-27 17:02 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 6
2022-05-20 17:08 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 6
2022-05-18 17:03 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 6
2022-05-16 07:13 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 10
2022-05-16 07:03 ET
Instil Bio, Inc. reported for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Instil Bio, Inc. reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Instil Bio, Inc. reported for 2022 q1
SEC form 6
2022-05-03 17:01 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 6
2022-03-30 16:20 ET
Instil Bio, Inc. published news for 2021 q4
SEC form 10
2022-03-07 07:14 ET
Instil Bio, Inc. published news for 2021 q4
SEC form 6
2022-03-07 07:05 ET
Instil Bio, Inc. published news for 2021 q4
SEC form 10
2022-03-07 00:00 ET
Instil Bio, Inc. published news for 2021 q4
SEC form 8
2022-03-07 00:00 ET
Instil Bio, Inc. published news for 2021 q4
SEC form 6
2021-12-17 17:00 ET
Instil Bio, Inc. published news for 2021 q3
SEC form 6
2021-11-15 07:19 ET
Instil Bio, Inc. published news for 2021 q3
SEC form 10
2021-11-15 07:16 ET
Instil Bio, Inc. published news for 2021 q3
SEC form 6
2021-11-15 07:10 ET
Instil Bio, Inc. published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Instil Bio, Inc. published news for 2021 q3
SEC form 6
2021-09-16 07:11 ET
Instil Bio, Inc. published news for 2021 q2
SEC form 6
2021-09-13 16:02 ET
Instil Bio, Inc. published news for 2021 q2
SEC form 10
2021-08-12 16:04 ET
Instil Bio, Inc. published news for 2021 q2
SEC form 6
2021-08-12 16:00 ET
Instil Bio, Inc. published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Instil Bio, Inc. published news for 2021 q2
SEC form 6
2021-05-13 16:40 ET
Instil Bio, Inc. published news for 2021 q1
SEC form 10
2021-05-13 16:38 ET
Instil Bio, Inc. published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
Instil Bio, Inc. published news for 2021 q1
SEC form 6
2021-04-27 17:23 ET
Instil Bio, Inc. published news for 2021 q1
SEC form 6
2021-04-13 16:48 ET
Instil Bio, Inc. published news for 2021 q1
SEC form 6
2021-03-23 16:22 ET
Instil Bio, Inc. published news for 2020 q4